Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$9.41
-0.41 (-4.18%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-37.6M · quality 47.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.9B
P/E
117.6x
↑EV/EBITDA
52.8x
↑ROE
4.6%
↑Gross Margin
54.7%
↑Debt/Equity
0.52
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.2%
FCF CAGR
—
FCF margin
6.4%
FCF / Net income
0.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $276.8M · net income $19.0M · FCF $17.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $276.8M | $276.8M | $174.2M | $235.9M | $274.8M |
| Net Income | $19.0M | $19.0M | $-78.3M | $-50.7M | $9.0M |
| EBITDA | $70.8M | $70.8M | $-43.5M | $-10.7M | $59.8M |
| EPS | 0.05 | 0.05 | -0.19 | -0.12 | 0.02 |
| Gross Margin | 54.7% | 54.7% | 56.0% | 68.3% | 67.9% |
| Operating Margin | 8.7% | 8.7% | -39.1% | -9.5% | -10.7% |
| Net Margin | 6.9% | 6.9% | -44.9% | -21.5% | 3.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.52 | 0.52 | 0.54 | 0.31 | 0.40 |
| Current Ratio | 0.66 | 0.66 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $17.7M | $17.7M | $-65.7M | $-37.6M | $-7.8M |
| Returns | |||||
| ROE | 4.6% | 4.6% | -19.9% | -10.8% | 1.8% |
| Valuation | |||||
| P/E | 117.63 | 117.63 | — | — | 374.50 |
| EV/EBITDA | 52.81 | 52.81 | — | — | 59.63 |
| P/B | 8.69 | 8.69 | 19.00 | 6.34 | 6.57 |
| Growth & Yield | |||||
| Revenue Growth | 58.9% | 58.9% | -26.2% | -14.1% | — |
| EPS Growth | 126.3% | 126.3% | -58.3% | -700.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
155.6%
EPS terminal req.
$0.83
Spread vs growth
-29.3%
5Y implied EPS CAGR
82.4%
EPS terminal req.
$1.01
Spread vs growth
43.9%
10Y implied EPS CAGR
41.7%
EPS terminal req.
$1.63
Spread vs growth
84.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+21.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.19 → 0.05
Residual
+21.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.